313235-17-5

Upstream product

• 5344-90-1 2-Aminobenzyl alcohol 
• 90312-02-0 N-(2-hydroxymethylphenyl)-4-methylbenzenesulfonamide 
• 243844-35-1 N-[2-(chloromethyl)-phenyl]-4-methylbenzene-1-sulfonamide 
• 1258868-61-9 (S)-1-(tert-butylsulfonyl)-2-vinylindoline 
• 313235-16-4 tert-butyl (2S)-2-vinylindolinecarboxylate 

Downstream Products

• 313235-07-3 1-((2S)-2-vinylindolinyl)-2-{4-[(4-methylphenyl)methyl]piperazinyl}ethan-1-one 
• 313234-77-4 1-((2S)-2-vinylindolinyl)-2-{4-[(4-chlorophenyl)methyl]piperazinyl}ethan-1-one 

Relevant academic research and scientific papers

Palladium(II)-catalyzed aerobic intramolecular allylic C[sbnd]H activation for the synthesis of indolines

A method for the preparation of indolines via palladium-catalyzed aerobic intramolecular allylic C[sbnd]H activation was developed. Oxygen was successfully used as oxidant with catalytic amount of 1,4-benzoquinone. 16 examples were reported, the majority of substrates gave moderate to good yields.

Hg(OTf)2-BINAPHANE-catalyzed enantioselective anilino sulfonamide allyl alcohol cyclization

Chiral ligands: Hg(OTf)2-catalyzed cyclization of anilino sulfonamide allyl alcohol is described; this reaction gives 2-vinyl indoline derivatives in good yields and excellent enantioselectivity by using a chiral BINAPHANE ligand (see scheme).

Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 2: Asymmetric synthesis and biological evaluation

A series of chiral benzylpiperazinyl-1-(2,3-dihydro-indol-1-yl)ethanone derivatives were prepared and examined for their affinity at dopamine D2 and D4 receptors. Three compounds having D2/D4 affinity ratios approximating that found for the atypical neuroleptic clozapine were further evaluated in behavioral tests of antipsychotic efficacy and motor side effects.

Benzylpiperazinyl-indolinylethanones

Disclosed are benzylpiperazinyl-indolinylethanone compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAAreceptors in tissue samples.